<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="12019">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02950467</url>
  </required_header>
  <id_info>
    <org_study_id>15-17825</org_study_id>
    <nct_id>NCT02950467</nct_id>
  </id_info>
  <brief_title>Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors</brief_title>
  <official_title>Psilocybin-assisted Group Therapy for Demoralization in Long-term AIDS Survivors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua Woolley</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Heffter Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>River Styx Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Usona Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Stupski Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether psilocybin-assisted group psychotherapy is
      a safe and feasible treatment for demoralization in long-term AIDS survivors (LTAS).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is an open-label mixed-methods pilot study of an individual oral psilocybin drug
      session combined with eight sessions of an evidence-based, manualized brief group
      psychotherapy for existential distress in palliative care patients. This study aims to
      include at least two therapy groups of at least four members each.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>July 2017</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">July 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of treatment-related adverse events as assessed by DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events, Version 2.0</measure>
    <time_frame>Enrollment to 3-month follow up, about 6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Subject recruitment and retention</measure>
    <time_frame>Duration of study, about 24 months</time_frame>
    <description>Two therapy groups of at least 4 subjects each will complete the study</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Demoralization Scale-II at endpoint</measure>
    <time_frame>Baseline and endpoint (10 weeks duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Demoralization Scale-II at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inventory of Complicated Grief at endpoint</measure>
    <time_frame>Baseline and endpoint (10 weeks duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Inventory of Complicated Grief at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Center for Epidemiologic Studies Depression Scale-Revised at endpoint</measure>
    <time_frame>Baseline and endpoint (10 weeks duration)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Center for Epidemiologic Studies Depression Scale-Revised at 3-month follow-up</measure>
    <time_frame>Baseline and 3-month follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in slope of Group Questionnaire pre-psilocybin and post-psilocybin</measure>
    <time_frame>Weeks 1, 3, 8 and 10</time_frame>
    <description>Group cohesion measure</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Distress</condition>
  <condition>Depression</condition>
  <condition>Grief</condition>
  <arm_group>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Modified brief Supportive-Expressive Group Therapy will be administered as eight weekly sessions. Oral psilocybin will be administered once in a clinical setting.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Psilocybin</intervention_name>
    <description>One individual oral psilocybin treatment session</description>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
    <other_name>4-phosphoryloxy-N,N-dimethyltryptamine</other_name>
    <other_name>Indocybin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Modified brief Supportive Expressive Group Therapy</intervention_name>
    <description>Eight sessions of weekly manualized group therapy</description>
    <arm_group_label>Group therapy plus psilocybin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criterion:

          -  Older gay-identified men who are long-term AIDS survivors and suffer from
             moderate-to-severe demoralization.

        Exclusion Criteria:

          -  A physical, neurological or cognitive condition that makes participating in the study
             unsafe or unfeasible.

          -  Regular psychotropic medication use.

          -  Personal or family history of serious mental illness.

          -  Severe depression requiring immediate standard-of-care treatment.

          -  Current substance use disorder (other than tobacco).

          -  Exclusion by the clinical judgment of the study investigators.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua Woolley, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian Anderson, MD,MSc</last_name>
    <role>Study Director</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Anderson, MD</last_name>
    <phone>415-476-7592</phone>
    <email>brian.anderson@ucsf.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Win Huynh, BS</last_name>
    <phone>415-221-4810</phone>
    <phone_ext>24117</phone_ext>
    <email>win.huynh@ucsf.edu</email>
  </overall_contact_backup>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>October 26, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Francisco</investigator_affiliation>
    <investigator_full_name>Joshua Woolley</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>HIV/AIDS</keyword>
  <keyword>Demoralization</keyword>
  <keyword>Psilocybin</keyword>
  <keyword>Group therapy</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Psilocybine</mesh_term>
    <mesh_term>N,N-Dimethyltryptamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
